Source: PharmaLive
Area: News
According to a PharmaLive report, the National Institute for Health and Clinical Excellence (NICE) has agreed to review an appeal against its preliminary decision not to recommend ranibizumab for the treatment of visual impairment due to diabetic macular oedema (DMO) (Final Appraisal Determination issued in July 2011 - see link below). An appeal hearing will be held in October 2011 and the appeal panel will send its decision to NCE within 15 working days.
Uncategorized